ALIGNANT astrocytomas are the most common primary brain tumors, accounting for 80% of all gliomas in adult patients. 3 Of these lesions, GBMs, which represent 50.7% of gliomas in adults, are the most common. 5 The incidence of GBM peaks between the 7th and 9th decades of life, making it more common in the elderly (those Ն 65 years of age). Anaplastic astrocytomas are less common than GBMs (accounting for 10-15% of gliomas) in the elderly, but are treated similarly. Both GBM and AA are increasing in absolute and age-adjusted incidences.
Clinical Materials and Methods

Data Sources
The National Cancer Institute's SEER-Medicare linked data were used for analysis. 34 For each linked data set, 94% of individuals in the SEER data set who were Ն 65 years old were matched to the Medicare database. 34 Medicare is the primary health insurer for 97% of elderly individuals in the US. The SEER program collects incident cancer cases with information on demographics, prognosis, treatment, primary tumor site, and histology, and represents 26% of the US population (http://seer.cancer.gov). The following Medicare files were used: 1) the MEDPAR file for hospitalizations (Part A), 2) the physician/supplier (NCH) file for physician visits and physician-performed procedures (Part B), and 3) the hospital outpatient (OUTSAF) file for outpatient procedures (Part B).
The study was approved by the H. Lee Moffitt Cancer Center and Research Institute Scientific Review Committee and the University of South Florida Institutional Review Board. All study hypotheses were formulated during the data collection phase of the study.
Study Sample Selection
A total of 1753 individuals with a primary GBM and 205 individuals with a primary AA diagnosed between June 1, 1991, and December 31, 1999 , and who were Ն 66 years of age at diagnosis were linked with Medicare claims from January 1, 1991, to December 31, 2001 . Anaplastic astrocytoma and GBM were defined by ICD-O-3 morphology codes 36 : GBM, 9440, 9441, and 9442; and AA, 9401 and 9411. All individuals had Medicare Parts A and B and were not members of an HMO during the period from 6 months before through 12 months after diagnosis. The following were also inclusion criteria: microscopic confirmation of tumor; age as sole reason for Medicare entitlement; and reporting source being a hospital, laboratory, private doctor, or nursing/convalescent home.
Treatment Patterns
Treatment procedures were defined using ICD-9-CM codes 35 (MEDPAR) and the Healthcare Common Procedure Coding System codes from the 2001 Current Procedural Terminology Manual 1 (NCH and OUTSAF) as: biopsy (stereotactic or regular), 0111-0119 and 61140, 61156, 61250, 61750, and 61751; surgery (craniotomy/craniectomy), 0120-0125 and 61304-61616; radiation therapy, 9220-9229 and 77401-77499; and chemotherapy, 9925, 96400-96549, and Q0083-Q0085. Duplicate treatment records were eliminated, with records in the NCH file taking precedence, followed by MEDPAR and OUTSAF for 12 months after diagnosis. 34 With the most invasive treatment taking priority, a hierarchical structure was used to compare common treatments with SEER. Treatment data from SEER records included radiation therapy, biopsy, and surgery. If an individual underwent cancer-directed biopsy procedure of any type (incisional, needle, or aspiration), he or she was coded as receiving a biopsy; otherwise patients were coded as not having surgery or having surgery using the reason for no surgery variable.
The 5 mutually exclusive treatment patterns of interest were: surgery only; biopsy only; biopsy and radiation; surgery and radiation; and surgery, radiation and chemotherapy. All other treatment combinations were grouped into the "other" category due to small sample sizes.
Comorbid Conditions
Preexisting comorbid conditions were assessed for the period from 6 months before up to 1 month before diagnosis of AA or GBM. These comorbidities were assessed via diagnosis codes and categorized using the Deyo comorbidity scale (excluding metastatic solid tumor and any malignancy categories). 10, 19 The number of comorbidities was dichotomized into no comorbidities or Ն 1 comorbidities because of small sample size for individuals with Ն 2 comorbidities.
Demographic and Clinical Variables of Interest
The main variables of interest were age at diagnosis, marital status, total number of comorbidities, race/ethnicity, sex, 1990 Census tract median household income, location of tumor in brain, and SEER region. Age at diagnosis was classified as 66-74 years or Ն 75 years and marital status was classified as married or not married (never married, separated, divorced, or widowed). The racial groups included were white, black, and "other" (American Indian, Chinese, Japanese, Filipino, Hawaiian, Korean, Asian Indian, Vietnamese, Tongan, and "other Asian"). The SEER regions were defined as Northeast (Connecticut), South (Georgia), Midwest (Michigan and Iowa), and West (California, Hawaii, state of Washington, Utah, and New Mexico). The 1990 Census tract median household income was used to dichotomize individuals into income categories of low income (Յ $30,000) and high income (Ն $30,001), where $30,000 was the median income value for all individuals combined. The ICD-O-3 topography codes were used to classify the location of tumors as supratentorial (cerebrum, frontal, temporal, parietal, or occipital), other (cerebellum, brainstem, ventricle, brain, or "not otherwise specified"), or involving overlapping regions of the brain. Performance status (Karnofsky Performance Scale score) was not available as it is not recorded in the SEER registry.
Statistical Analysis
All statistical analyses were stratified by lesion histological type. Patient age differences were assessed using the chi-square test or the Fisher exact test generating two-sided probability values. Kappa statistics were calculated to determine the extent of agreement for overlapping treatments between SEER and Medicare for the individual treatment records with a 95% CI and a McNemar two-sided probability value. Unconditional logistic regression was used to estimate OR and 95% CI to measure the association between treatment and age at diagnosis. Survival differences, by lesion histological type, patient age at diagnosis, and treatment were examined using Kaplan-Meier 16 and Cox proportional hazards 8 models to calculate adjusted median survival and adjusted HR and 95% CI. Survival was defined as the time from AA or GBM diagnosis until death from any cause. All multivariable models were adjusted for sex, race/ethnicity, location of tumor, number of comorbidities, SEER region, median household income, and marital status. Variables of interest were tested for the propor-tional hazards assumption and no violations were found. 20 All data were analyzed using SAS version 9.1 (SAS Institute, Inc.) and S-Plus version 6.2 (Insightful Corp.).
Results
The average age at diagnosis for AA was 74.4 years and for GBM was 74.1 years. Significant age differences existed by total number of comorbidities and median income for AA and by marital status and total number of comorbidities for GBM (Table 1) . Other demographic features, including race/ethnicity, sex, and tumor location, were similar in both groups.
Based on the significant overlap agreement between the SEER and Medicare files for receipt of radiation, biopsy, and surgery, the Medicare treatment codes were used in all further analyses (Table 2) .
Overall for individuals with an AA, there was no difference in treatment type distribution by age at diagnosis (p = 0.13) except for those receiving an "other" treatment combination (p = 0.04, Table 3 ). The odds of receipt of a particular treatment did not vary by age at diagnosis for individuals with AA (Table 4) .
Overall for individuals with GBM, the distribution of treatment patterns differed significantly by age at diagnosis for all treatment patterns except the "other" treatment category (Table 3) . A higher proportion of individuals who were Ն 75 years of age had single treatments, while a higher proportion of individuals Ͻ 75 years of age had multiple treatments. For individuals with GBM, the odds of having specific treatment combinations varied significantly by age at diagnosis. Individuals with GBM who were Ն 75 years old had a 2.5-fold increased odds of having biopsy only (OR 2.53, 95% CI 1.78-3.59), a 1.5-fold increased odds of having surgery only (OR 1.47, 95% CI 1.15-1.87), a 31% decreased odds of having radiation and surgery (OR 0.69, 95% CI 0.57-0.84), and a 65% decreased odds of having chemotherapy, radiation, and surgery (OR 0.35, 95% CI 0.23-0.53) compared with those Ͻ 75 years of age (Table 4).
The median survival of individuals with AA or GBM was similar and ranged from 2 months for those treated with biopsy or surgery only to 9 months for patients with GBM treated with surgery, radiation, and chemotherapy (Table 5 and Fig. 1 ). No differences in median survival were noted by patient age or tumor histological characteristics. In contrast, there were significant differences in adjusted survival by patterns of treatment. Adjusted median survival was lowest for those who received biopsy only or surgery only regardless of lesion histological type or patient age at diagnosis.
For individuals with AA, individuals treated with a biopsy only (66-74 years of age, HR 4.00, 95% CI 1.62-9.91; Ն 75 years of age, HR 3.92, 95% CI 1.56-9.86) had a 3.9-to 4.0-fold increased risk of death compared with individuals who received the standard of care, which was surgery and radiation therapy (Table 5) . Individuals with a GBM who had biopsy only, surgery only, or radiation and biopsy had an increased risk of death, ranging from 1.6-to 6.9-fold regardless of age at diagnosis, compared with those who received both surgery and radiation therapy. In- Discussion Malignant astrocytomas, comprising AA and GBM, are the most common primary brain tumors in adults, particularly in those Ն 65 years old at diagnosis. The frequency of these tumors has increased in those Ն 65 years of age by 7-23% yearly.
14,15,29 While demographic, clinical, and treatment characteristics of cases of malignant astrocytoma involving individuals Ͻ 65 years old at diagnosis has been well studied, 2, 6, 9, 25, 26 there has been little study of this disease in the elderly. This lack of information is problematic, as the elderly account for more than 20% of cancer patients and represent the fastest growing segment of the US population. 37, 38 During the period of this study (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) , at most institutions the "standard of care" for individuals in whom AA or GBM was diagnosed before 65 years of age consisted of surgery and radiotherapy with or without chemotherapy. 6, 26 Nevertheless, a variety of approaches were advocated for the treatment of elderly individuals, and no specific standard of care has been widely recognized. 6 Although several reports of practice patterns have been published, they have been primarily from single institutions or groups of institutions.
Mahaley et al. 25 performed a survey of patterns of care of individuals with brain tumors in the US from 1980 to 1985. Although the extent of surgery and use of radiotherapy were analyzed, the survey methodology was not population-based, and there was no specific analysis of treatment patterns in the elderly. In the Glioma Outcomes Project, 788 individuals with newly diagnosed Grade III-IV gliomas were prospectively identified and followed up at 52 sites between 1997 and 2001. 6, 7, 22 Overall, the investigators noted that 41% of these individuals were Ͼ 60 years and found that those individuals with GBM were more likely to be treated with aggressive therapies than those with AA, but no specific analysis of data pertaining to elderly individuals was performed. The Minnesota Cohort Study was a hospital-based review of patterns of care in 714 cases involving elderly individuals (Ͼ 65 years of age) with GBM from 1980 to 1995; the authors found a decreased use of combination treatments compared with earlier periods. 23 Magrini and colleagues 24 demonstrated that age, extent of resection, radiotherapy, and chemotherapy contributed to differences in prognosis in multivariate analysis in their study of 1722 individuals of varying ages treated at 12 radiation oncology centers in Italy. The results of 3 additional single-institution studies have also suggested that elderly individuals undergoing aggressive resection followed by radiotherapy do better than those treated less aggressively. 27, 31, 33 These studies involved small groups of patients (30-108 individuals), however, and the only age-at-diagnosis classifications used were Ͼ 65 or Յ 65 years. In contrast, Glantz et al. 13 studied 86 consecutive cases involving patients Ͼ 70 years old at 3 institutions and found no difference in survival by treatment modality (surgery followed by radiotherapy or primary temozolomide-based chemotherapy). A recent study of 81 elderly patients with GBM (Ն 70 years of age) showed that independent of extent of resection, those who received radiotherapy plus supportive * chemo = chemotherapy; strat = stratified. † Probability value generated by chi-square or Fisher exact test. ‡ For individuals with AA, "other" includes no treatment; radiation only; surgery and chemotherapy; biopsy, radiation, and chemotherapy; and surgery, radiation, and chemotherapy. For individuals with GBM, "other" includes no treatment; radiation only; chemotherapy only; biopsy and chemotherapy; surgery and chemotherapy; radiation and chemotherapy; and biopsy, radiation, and chemotherapy. care had improved survival and time to progression compared with those who received supportive care alone. 17 Finally, members of our group and others 2, 9 have conducted earlier analyses of patterns of diagnosis and survival using data from the Public-Use SEER database for individuals in whom lesions were diagnosed between 1973 and the early to late 1990s. However, these studies did not permit specific and complete analysis of patterns of care in the elderly populations.
Thus, the aforementioned studies do not generally compare with the current population-based study of 1753 individuals in the US, which focused on assessing patterns of care and their association with age at diagnosis and tumor histological type in elderly patients. Patterns of treatment among elderly individuals with AA did not vary by age except for the use of unconventional therapies, which were used less frequently in individuals Ն 75 years old. In contrast, for individuals with GBM, the odds of undergoing less aggressive treatment increased significantly for those who were Ն 75 years of age compared with those who were Ͻ 75 years old at diagnosis. The odds of undergoing aggressive treatment-surgery followed by radiation with or without chemotherapy, which was the "standard of care" in the younger individuals-decreased significantly in individuals Ն 75 years of age.
Overall, the demographic distribution and survival of elderly individuals with malignant astrocytomas in this study was similar to that reported in previous papers. 6, 11, 12, 18, [23] [24] [25] 28, 30, 32, 35 Interestingly, however, there were no differences in median survival by treatment pattern when we stratified by histological type of tumor and patient age at diagnosis, which contradicts previous observations made by others of a dominant effect of age on overall survival in elderly individuals by histological type of tumor. Our observation of a lack of difference in median survival is a novel one; we were unable to find any previous studies that addressed differences in outcome in elderly individuals by age, tumor histological characteristics, and treatment type. The lack of prognostic difference between AA and GBM is similar to outcome data from the Central Brain Tumor Registry of the United States (CBTRUS) 5 and probably reflects the aggressive nature of high-grade gliomas in the elderly regardless of histological type (GBM or AA). * Odds ratios were adjusted for race/ethnicity, sex, number of comorbidities, location of tumor in brain, marital status, median household income, and SEER registry region. Abbreviation: Adj = adjusted.
† For individuals with AA, "other" includes no treatment; radiation only; surgery and chemotherapy; biopsy, radiation, and chemotherapy; and surgery, radiation, and chemotherapy. For individuals with GBM "other" includes no treatment; radiation only; chemotherapy only; biopsy and chemotherapy; surgery and chemotherapy; radiation and chemotherapy; and biopsy, radiation, and chemotherapy. † Probability value Ͻ 0.005. ‡ Probability value Ͻ 0.001. § For individuals with AA, "other" includes no treatment; radiation only; surgery and chemotherapy; biopsy, radiation, and chemotherapy; and surgery, radiation, and chemotherapy. For individuals with GBM "other" includes no treatment; radiation only; chemotherapy only; biopsy and chemotherapy; surgery and chemotherapy; radiation and chemotherapy; and biopsy, radiation, and chemotherapy.
In contrast, we found significant differences in survival according to patterns of treatment. Compared with individuals treated with surgery and radiation, individuals with an AA who had biopsy only had approximately a 4-fold increased risk of death regardless of age (Table 5) . Similarly, elderly individuals with a GBM treated with biopsy only, surgery only, or biopsy and radiation had an increased risk of death compared with those treated with surgery and radiation, the "standard of care." Conversely, elderly patients with GBM who were treated with surgery, radiation therapy, and chemotherapy had a significantly decreased risk of death compared with those receiving surgery and radiation alone. Although there was also a trend for improved survival among individuals Ն 75 years old who were treated with this combination of therapies, it was not statistically significant. Whether the improved survival of individuals undergoing more aggressive treatments reflects the efficacy of the treatment or simply a selection bias, as has been previously suggested, 13, 17, 23, 27, 31, 32 could not be addressed in this study.
The available linked Medicare data allowed us to ascertain full first-course-of-treatment information in addition to information on comorbidities and socioeconomic status. In addition, since all of the individuals in the study had the same type of health insurance for the entire period of the study (Medicare Parts A and B and no HMO membership), discrepancies in treatment by age are not likely to be dependent on disparities in access to health care. We cannot, however, distinguish between those individuals who had supplemental insurance policies and those who did not, as this information is not available in the data set under study. We acknowledge that there are also limitations to the use of the SEER-Medicare linked data used in this study. The results of this analysis are only generalizable to persons in whom AA or GBM has been diagnosed and who are Ն 66 years of age. Because we used Medicare-linked data, our study did not include individuals whose health care was paid for by third-party insurance or other government-sponsored programs or those who paid for the care themselves. We were also unable to adjust for Karnofsky Performance Scale score, as neither SEER nor Medicare collected this information, which can affect treatment decisions for both physicians and patients. The reasons why individuals would choose one treatment pattern compared with another treatment pattern are also not available in these data. Finally, it should also be noted that this analysis is based on findings obtained during a period prior to the widespread adoption of temozolomide, an effective and well-tolerated oral chemotherapeutic agent now used as a part of the standard of care for patients < 70 years of age with newly diagnosed GBM. 30 Thus, we were not able to evaluate the use or the effects of this important new therapy in this elderly population.
Conclusions
Age at diagnosis appears to correlate with treatment patterns among elderly individuals with GBM but not among those with AA. Individuals with GBM who were Ն 75 years of age at diagnosis were less likely to receive aggressive treatment such as surgery and radiotherapy with or without chemotherapy. This pattern of treatment was associated with a higher risk of death in these individuals and hence shortened survival. Further investigation of other large population-based databases is needed to confirm these findings. 
